• Explore /
  • Poster
  • / A phase 2A open-label, multicenter trial of the safety and efficacy of LYC-55716, a first-in-class oral, small-molecule RORγ agonist to treat select solid tumors.

A phase 2A open-label, multicenter trial of the safety and efficacy of LYC-55716, a first-in-class oral, small-molecule RORγ agonist to treat select solid tumors.

Abstract Poster

Authors

Karen Kelly

Karen Kelly

University of California Davis Comprehensive Cancer Center, Sacramento, CA

Karen Kelly , Melissa Lynne Johnson , Devalingam Mahalingam , Stephen V. Liu , Hope Elizabeth Uronis , Christina Wu , Laura Carter , Xiao Hu , Garry Alan Weems , H. Jeffrey Wilkins , Linda R. Duska

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics and Translational Research

Sub Track

Small Molecules

Clinical Trial Registration Number

NCT02929862

Citation

J Clin Oncol 36, 2018 (suppl; abstr TPS2617)

DOI

10.1200/JCO.2018.36.15_suppl.TPS2617

Abstract #

TPS2617

Poster Bd #

432b

Abstract Disclosures

Similar Posters

First Author: Bunpei Miyazaki

First Author: Aung Naing

First Author: Arvind Dasari

First Author: Amna Falak Sher